市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Traws Pharma, Inc. | 混合的 | - |
AIStockmoo 评分
-0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -2.5 |
| 宏观环境 | 0.0 |
| AI Insight | NA |
| 平均 | -0.17 |
|
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 18.86% |
| 机构持股比例 | 31.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Orbimed Advisors Llc | 30 Jun 2026 | 1,203,260 |
| Lynx1 Capital Management Lp | 30 Jun 2026 | 559,470 |
该时间范围内无数据。
该时间范围内无数据。
投资组合